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ABSTRACT
Background
The clinical relevance of infections with the novel human coronavirus NL63 (HCoV-NL63) has
not been investigated systematically. We therefore determined its association with disease in
young children with lower respiratory tract infection (LRTI).
Methods and Findings
Nine hundred forty-nine samples of nasopharyngeal secretions from children under 3 y of
age with LRTIs were analysed by a quantitative HCoV-NL63-specific real-time PCR. The samples
had been collected from hospitalised patients and outpatients from December 1999 to October
2001 in four different regions in Germany as part of the prospective population-based PRI.DE
study and analysed for RNA from respiratory viruses. Forty-nine samples (5.2%), mainly derived
from the winter season, were positive for HCoV-NL63 RNA. The viral RNA was more prevalent in
samples from outpatients (7.9%) than from hospitalised patients (3.2%, p ¼ 0.003), and co-
infection with either respiratory syncytial virus or parainfluenza virus 3 was observed
frequently. Samples in which only HCoV-NL63 RNA could be detected had a significantly higher
viral load than samples containing additional respiratory viruses (median 2.1310
6 versus 2.73
10
2 copies/ml, p ¼ 0.0006). A strong association with croup was apparent: 43% of the HCoV-
NL63-positive patients with high HCoV-NL63 load and absence of co-infection suffered from
croup, compared to 6% in the HCoV-NL63-negative group, p , 0.0001. A significantly higher
fraction (17.4%) of samples from croup patients than from non-croup patients (4.2%) contained
HCoV-NL63 RNA.
Conclusion
HCoV-NL63 infections occur frequently in young children with LRTI and show a strong
association with croup, suggesting a causal relationship.
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Respiratory tract infections are among the most frequent
diseases in the ﬁrst years of life. Although there is a large
number of viruses that are known to be involved in
symptomatic respiratory tract infections, including respira-
tory syncytial virus (RSV), inﬂuenza virus (INF), parainﬂuenza
virus (PIV), and human metapneumovirus, none of the known
pathogens is detected in a substantial number of cases.
Recently we identiﬁed a novel coronavirus in a child with
bronchiolitis: human coronavirus NL63 (HCoV-NL63) [1,2].
This virus, together with SARS-CoV, is one of the new
members of the Coronaviridae family [3–6].
Screening of respiratory samples in Amsterdam and
Rotterdam conﬁrmed that HCoV-NL63 is circulating among
humans with respiratory disease in the Netherlands [1,7]. To
investigate the prevalence of HCoV-NL63 and its involve-
ment in respiratory diseases, we now analysed 949 samples
from the Paediatric Respiratory Infection in Germany
(PRI.DE) study, a prospective population-based study on
lower respiratory tract infections (LRTIs) in children under 3
y of age in Germany [8,9]. The PRI.DE study represents the
German population by (i) including multicentre sampling
(one city each in the north, east, south, and west of the
country) and by (ii) recruiting children in paediatric practices
and in referral children’s hospitals. We were particularly
interested in the presence of HCoV-NL63 in respiratory
disease for which no other viral pathogen could be detected,
in order to identify clinical symptoms associated with HCoV-
NL63 infection. Nasopharyngeal secretion (NPS) of the
patients had already been tested for RSV, INF, and PIV, the
principal viruses responsible for LRTI in young children [8].
However, RNA of these viruses could not be detected in 58%
of samples for outpatients and 51% of samples for
hospitalised patients. A second study that examined a subset
of these negative samples for human metapneumovirus RNA
showed that this virus could be detected in only 0.3% of the
patients [9]. To explore the potential contribution of HCoV-
NL63 to LRTI and to deﬁne clinical symptoms associated with
HCoV-NL63 infection, a subset of the PRI.DE samples were
analysed in this study by a HCoV-NL63-speciﬁc quantitative
real-time RT-PCR.
Methods
Participants and Materials
The PRI.DE study is a population-based prospective Ger-
man multicentre study. Patients from Hamburg, Bochum,
Freiburg, and Dresden are been included from paediatric
practices (outpatients) or hospitals (inpatients) [8]. Children
were recruited from November 1999 to October 2001 and
included in the study if they showed clinical signs of
laryngotracheitis (croup), bronchitis, bronchiolitis, pneumo-
nia, or apnoea, the last only in infants less than 6 mo of age.
Signs and symptoms of clinical diagnoses were deﬁned
according to criteria of Denny and Clyde [10]. The deﬁnition
of croup in the inclusion criteria was hoarseness of voice,
barking cough, and inspiratory stridor due to laryngeal
obstruction. Before the start of the study this deﬁnition had
been consented to by the heads of the participating hospitals
and had been communicated in writing (study protocol) as
well as verbally (investigators meetings in the different cities)
to the participating physicians. NPS was taken in a stand-
ardised manner by introducing a wetted catheter through the
lower nasal meatus into the epipharynx and retracting it with
a suction of 200 Pa. Liquid nitrogen freezers had been
situated at every practice/hospital to snap freeze the speci-
men immediately after collection. The samples were trans-
ported to the central testing laboratory on dry ice. RNA was
extracted from 220 ll of NPS using the Qiamp Viral RNA
Mini Kit (Qiagen, Hilden, Germany) and eluted in 50 llo f
preheated RNase free water (80 8C) for 5 min. The Hexaplex
PCR test kit (Prodesse, Milwaukee, Wisconsin, United States)
was used to test for the presence of genomic material of seven
respiratory viruses: RSV-A, RSV-B, PIV1, PIV2, PIV3, INF A,
and INF B [8,11]. The remaining RNA was stored in a  70 8C
freezer.
Of the total of 3,654 NPSs that were collected within the
PRI.DE study, half were randomly assigned to this study.
Randomisation was performed via a program generating
random numbers in order to distribute the samples equally
between two different laboratories. Randomisation was
performed separately for each study centre. A subgroup of
949 samples, for which sufﬁcient amounts of RNA were
available, were tested for HCoV-NL63 RNA without knowl-
edge of the result of the Hexaplex assay. For a number of
important parameters the 949 samples were a proper
representation of the complete PRI.DE study (shown in Ta-
ble 1). Samples from all seasons were roughly equally
represented (20.0% of all samples were collected in the
winter months December/January/February, 32.9% of all
samples were from March/April/May, 38.9% of all samples
were from June/July/August, and 28.0 % of all samples were
collected in September/October/November). The only period
from which only a few samples were analysed was December
1999 to March 2000 (see Figure 1). The study protocol was
approved by the Ethics Committee of the University Hospital
Freiburg, and by the ethics committee of each participating
centre. Written informed consent was obtained from the
parents of all participants.
Laboratory Testing
For real-time HCoV-NL63 PCR, the primers repSZ-1 (59-
GTGATGCATATGCTAATTTG) and repSZ-3 (59-
CTCTTGCAGGTATAATCCTA) [1] were used with a com-
mercially available RT-PCR kit (QuantiTect Probe RT-PCR
Kit with separate addition of SYBR Green, Qiagen, Hilden,
Germany). RNA (5 ll) was reverse-transcribed in a ﬁnal
volume of 20 ll for 20 min at 50 8C followed by denaturation
at 95 8C for 15 min. Forty-nine cycles of PCR ampliﬁcation
were performed in a Rotor-Gene 3000 (Corbett-Research,
Mortlake, Australia) at 95 8C for 10 s, followed by an
annealing step for 1 min at 55 8C. Elongation was performed
at 72 8C for 30 s. Accumulation of PCR products was
monitored by measuring ﬂuorescence of intercalated SYBR
Green at 72 8C and 81 8C for 15 s. The speciﬁcity of the PCR
products of samples showing a relevant increase in SYBR
Green ﬂuorescence was conﬁrmed by melting point analysis
(peak at approximately 86 8C), by determining the size of the
PCR product (237 bp) through agarose gel electrophoresis,
and by hybridisation to an HCoV-NL63-speciﬁc internal
probe (59-AGGGTCCTCCTGGTAGTGGTAAGTCA-
CATTGTTCC). In addition, 17 of the positive PCR products
were sequenced to further conﬁrm the identity of the PCR
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cross-contamination during specimen extraction and PCR
ampliﬁcation. Negative controls included in each run did not
show a relevant increase of SYBR Green intercalation.
For quantitative evaluation, a PCR product of HCoV-NL63
was cloned in plasmid TOPO PCR II using the TA-cloning kit
of Invitrogen (Carlsbad, California, United States). RNA was
in vitro transcribed using the AmpliScribe T7 High Yield
Transcription Kit (Epicentre Technologies, Madison, Wis-
consin, United States) following the manufacturer’s instruc-
tions. The synthesised RNA was analysed by agarose gel
electrophoresis for intactness of the transcript, and the
concentration was determined by the Ribo-Green method.
Two independently transcribed RNA samples were adjusted
to 10
9 copies/ml, and RT-PCR analysis of serial dilutions of
both control RNAs revealed that ﬁve RNA copies per reaction
could be detected. This corresponds to a detection limit of
 225 copies/ml NPS. Both in vitro transcribed control RNAs
were also used to quantify the RNA copy number in the
supernatant of a HCoV-NL63-infected culture. Serial dilu-
Table 1. Demographic, Clinical, and Virological Characteristics of PRI.DE Study Population and the Patients included in HCoV-NL63
Analysis
Category Characteristic PRI.DE Study Patients (n [%])
a HCoV-NL63-Tested Patients (n [%])
b
Outpatients
(n ¼ 1,487)
Inpatients
(n ¼ 3,065)
Outpatients
(n ¼ 392)
Inpatients
(n ¼ 557)
Nosocomial cases 141 (4.6%) 31 (5.6%)
Study region Freiburg 512 (34.4%) 1,111 (36.2%) 118 (30.1%) 213 (38.2%)
Dresden 618 (41.6%) 460 (15.0%) 183 (46.7%) 96 (17.2%)
Bochum 202 (13.6%) 485 (15.8%) 47 (12.0%) 67 (12.0%)
Hamburg 155 (10.4%) 1,009 (32.9%) 44 (11.2%) 181 (32.5%)
Age 0–1 y 626 (42.1%) 1,838 (60.2%) 156 (39.8%) 349 (62.8%)
1–2 y 533 (35.8%) 844 (27.7%) 143 (36.5%) 155 (27.9%)
2–3 y 328 (22.1%) 369 (12.1%) 93 (23.7%) 52 (9.4%)
Male 827 (55.6%) 1,851 (60.9%) 218 (55.6%) 316 (57.2%)
Diagnosis
c Croup 201 (13.5%) 175 (5.7%) 51 (13.0%) 18 (3.2%)
Bronchitis 573 (38.5%) 406 (13.2%) 140 (35.7%) 86 (15.4%)
Wheezing bronchitis 777 (52.3%) 1,683 (54.9%) 204 (52.0%) 317 (56.9%)
Pneumonia 84 (5.7%) 1,042 (34.0%) 14 (3.6%) 191 (34.3%)
Apnoea 3 (0.2%) 108 (3.5%) 0 (0%) 20 (3.6%)
Virus detected
c RSV-A/B 381 (26.9%) 866 (38.7%) 118 (30.4%) 219 (40.0%)
PIV1/2/3 184 (13.0%) 193 (8.6%) 62 (16.0%) 57 (10.4%)
INF A/B 54 (3.8%) 87 (3.9%) 4 (1.0%) 18 (3.3%)
aFor virus detected, n ¼ 1,418 samples for outpatients and n ¼ 2,236 samples for inpatients.
bFor virus detected, n ¼ 388 samples for outpatients and n ¼ 548 samples for inpatients.
cMore than one diagnosis possible.
DOI: 10.1371/journal.pmed.0020240.t001
Figure 1. Seasonal Distribution of HCoV-NL63
Bars represent the percentage of HCoV-NL63-positive samples per month. Numbers above the columns for each month give the number of HCoV-
NL63-positive samples over the number of samples tested.
DOI: 10.1371/journal.pmed.0020240.g001
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used as standards in each run of the real-time RT-PCR. The
inter-assay variability of the crossing points of RT-PCR
samples containing between 260 and 260,000 copies was
below 2%, and the inter-assay variability of their copy
numbers was below 35%. Since 260 RNA copies per RT-
PCR reaction corresponds to a viral load of approximately
10
4 RNA copies/ml NPS, 10
4 copies/ml was taken as the lower
limit for accurate quantiﬁcation.
Statistical Methods
Calculations were performed using the SAS system, version
8.2 (SAS Institute, Cary, North Carolina, United States).
Proportions were compared using the v
2 test, and compar-
isons of viral load were performed by means of Wilcoxon’s
two-sample test. To determine the association of the
investigated viruses with disease (croup or not), odds ratios
and corresponding 95% conﬁdence intervals were derived in
separate bivariate calculations ﬁrst. The odds ratios present
the probability of croup in children infected with HCoV-
NL63 in relation to the probability of croup in patients not
infected with HCoV-NL63 within this population of patients
with LRTI. Results were conﬁrmed by performing a logistic
regression with occurrence of croup as the dependent
variable, and detection of RSV, PIV, or HCoV-NL63 as
independent variables. Double infections were thus ac-
counted for. INF could not be considered in the model,
because no INF-positive croup patients were found.
Results
HCoV-NL63 Infections
Of the 949 PRI.DE samples tested, 392 were from out-
patients at the four study sites, and the remaining 557
samples were from hospitalised patients. In total, 49 of the
949 samples (5.2%) were positive for HCoV-NL63. More
HCoV-NL63 infections were found in the outpatients (31
patients, 7.9%) than in hospitalised patients (18 patients,
3.2%, p ¼ 0.003). Various clinical diagnoses of lower
respiratory tract disease were given for the HCoV-NL63-
positive patients, including croup, bronchitis, bronchiolitis,
and pneumonia (Table 2). The ages of the HCoV-NL63-
infected children ranged from 0 to 2.9 y, with a median age of
0.7 y for the hospitalised patients and 1.5 y for the
outpatients. As may be expected based on knowledge of
other human coronaviruses, there is a strong seasonal
distribution of HCoV-NL63, with preferential detection in
the period between November and March (Figure 1). Peaks
were observed in December 2000 (14% of patients positive)
and February 2001 (12% of patients positive). We found no
positive samples in the winter months of 1999 and 2000, but
the analysed PRI.DE samples were unequally distributed and
only 17 samples were analysed from the period December
1999 to March 2000.
HCoV-NL63 Co-Infections with RSV-A and PIV3
Since the same samples had been tested previously for the
presence of RSV, PIV, and INF RNA [8], the HCoV-NL63-
positive samples were analysed for co-infections with these
viruses. Co-infections were apparent in 29 of the 49 HCoV-
NL63-positive samples: 20 patients were co-infected with
RSV-A, four with RSV-B, and ﬁve with PIV3. Double
infections were observed in the hospitalised patients with
HCoV-NL63 (72%) but also in the outpatients (52%). HCoV-
NL63 co-infection with RSV-A occurred predominantly in
the hospitalised patients (61%) rather than the outpatient
group (29%). In contrast, HCoV-NL63 co-infections with
PIV3 were exclusively present in the outpatient group (16%).
Similar trends were also observed when looking at the overall
prevalence of the viruses: RSV-A occurred in 32% of
hospitalised patients versus 21% of outpatients, and PIV3
occurred in 5% of hospitalised patients and 8% of out-
patients [8]. The RNA load of HCoV-NL63 differed consid-
erably from less than 225 copies/ml (but detectable) to 9310
7
copies/ml aspirate. Interestingly, the HCoV-NL63 load was
signiﬁcantly higher in samples with undetectable levels of the
other viral RNAs (median viral load 2.1310
6 copies/ml) than
in samples that had co-infections with RSV or PIV3 (2.7310
2
copies/ml, p ¼ 0.0006; Figure 2).
The HCoV-NL63 Load as a Function of Time after Infection
As mentioned above, the HCoV-NL63 load in the singly
infected group (n ¼ 20) was on average high, although there
were a few samples with a load below 10,000 copies/ml (n¼6).
The HCoV-NL63 load may be related to the date of sampling
relative to the onset of disease. We therefore compared the
viral load of these patients with the number of days after the
onset of disease that the sample was taken. For the group with
a high viral load (.10,000 copies/ml), the median time of
sampling after onset of disease was 2 d, whereas the median
interval was 6 d for the group with the lower viral load.
However, the variation in number of days from onset of
disease to sampling was high, and the difference between the
high and low viral load group was not statistically signiﬁcant
(p ¼ 0.11).
Association of HCoV-NL63 Infection with Clinical
Symptoms
The high frequency of co-infections in HCoV-NL63-
positive samples makes it difﬁcult to deﬁne HCoV-NL63-
induced symptoms. However, in 20 of the 49 HCoV-NL63-
positive samples no other virus (RSV, PIV, or INF) could be
detected. At least 14 of these samples also had a high viral
RNA load (.10,000 copies/ml aspirate), cases that may be best
suited to study the clinical symptoms associated with HCoV-
NL63 infection. Six of the 14 children (43%) of this group had
croup compared to only 54 of 900 HCoV-NL63-negative
children (6%, p , 0.0001). A similar high frequency of croup
(45%) was also observed for the 20 samples in which only
HCoV-NL63 RNA was detected, independent of the viral
load. The association of HCoV-NL63 with croup also held for
all analysed samples: 24% in the HCoV-NL63-positive group
had croup compared to 6% of the 900 HCoV-NL63-negative
patients (p , 0.0001). HCoV-NL63 was detectable in 17.4% of
all samples from croup patients. The chance of croup is
estimated to be 6.6 times higher in HCoV-NL63-positive
LRTI patients than in HCoV-NL63-negative LRTI patients
(95% conﬁdence interval 3.1–14.2), similar to that found for
PIV1, PIV2, and PIV3 (Table 3).
In addition to croup, we also observed bronchitis (n¼6, of
which one also had croup), bronchiolitis (n ¼ 3, of which one
also had croup), and pneumonia (n¼1) in the 14 patients with
a high HCoV-NL63 load. None of these diseases was
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NL63.
Discussion
The newly discovered coronavirus HCoV-NL63 was de-
tected in a considerable number of nasal aspirates of children
under the age of 3 y with LRTIs. With an overall occurrence
of 5.2%, it is the third most frequently detected pathogen in
this patient group, in which RSV is detected in 31.4%, PIV3 in
9.6%, PIV1 in 2.5%, INF A or INF B in 2.4%, and PIV2 in
0.6%. These viruses were detected with similar frequency in
the PRI.DE study [8], arguing against a bias during selection
of the analysed samples. HCoV-NL63 is more frequently
found in the outpatient group with LRTI (7.9%) than among
hospitalised patients (3.2%). PIV3 follows the same pattern
(8% and 5%, respectively), but the reverse pattern is observed
for RSV (21% and 32%, respectively; [8]). Thus, HCoV-NL63
Table 2. HCoV-NL63-Positive Patients
Group Patient
Number
a
Age
(Years)
Sex Sampling
Month/Year
Diagnosis Fever Other
Virus
HCoV-NL63
RNA Load
(Copies/Millilitre)
b
Hospital patients 10–343 1.88 F 12/00 Pneumonia N RSV-B 26,200
10–397 0.09 F 1/01 Bronchiolitis N RSV-A 4,520
10–416 0.11 M 2/01 Bronchitis N RSV-A 18,800
10–447 0.86 M 2/01 Croup/Bronchiolitis N — Positive ( 225)
11–275 2.23 M 12/00 Croup/Bronchiolitis Y — 7,380,000
11–395 0.78 F 3/01 Bronchiolitis Y RSV-A Positive ( 225)
20–443 0.65 M 1/01 Bronchiolitis N RSV-A Positive ( 225)
20–454 0.17 F 2/01 Bronchiolitis N RSV-A Positive ( 225)
30–317 0.08 F 2/01 Bronchiolitis Y RSV-B 667
40–489 0.22 F 12/00 Bronchitis N RSV-A Positive ( 225)
40–546
b 0.01 M 12/00 Bronchiolitis N RSV-A 1,360,000
40–713 0.99 F 2/01 Croup/Bronchitis Y — 53,600,000
40–715 0.76 M 2/01 Bronchiolitis N — Positive ( 225)
40–717 0.13 F 2/01 Pneumonia Y RSV-A Positive ( 225)
40–723 0.10 M 2/01 Bronchiolitis N RSV-A Positive ( 225)
40–735 1.05 F 2/01 Pneumonia Y RSV-A Positive ( 225)
40–746 1.80 F 2/01 Pneumonia N — 17,400,000
40–764 1.52 F 2/01 Pneumonia Y RSV-A Positive ( 225)
Outpatients 12–75 0.95 M 12/00 Croup N — 155,000
12–86 0.71 F 1/01 Bronchitis N — 2,240
12–107 1.02 M 3/01 Bronchiolitis N RSV-A 333
12–108 1.02 M 3/01 Bronchitis N RSV-A Positive ( 225)
12–137 1.25 M 9/01 Bronchiolitis N RSV-A Positive ( 225)
13–255 2.75 F 11/00 Bronchiolitis N PIV3 26,200
13–316 1.01 M 1/01 Croup Y PIV3 6,430,000
13–342 1.07 M 1/01 Croup N — 27,400,000
22–102 0.37 M 4/00 Bronchitis N — 5,240,000
22–136 1.08 F 11/00 Croup Y PIV3 571
22–140 2.15 F 11/00 Croup N PIV3 Positive ( 225)
22–143 1.51 M 11/00 Croup Y — Positive ( 225)
22–158 1.41 F 11/01 Bronchiolitis N RSV-A 333
22–170 2.33 M 1/01 Bronchitis Y RSV-B 548
22–195 2.09 M 2/01 Bronchiolitis N RSV-A 197,000
22–198 1.85 M 2/01 Bronchiolitis Y RSV-A Positive ( 225)
22–215 0.78 M 3/01 Croup Y — 25,000,000
23–66 2.03 M 12/00 Bronchitis N — 2,860,000
23–68 2.45 F 12/00 Bronchiolitis Y RSV-A 140,000
23–69 1.75 M 12/00 Croup N — Positive ( 225)
23–95 1.86 M 1/01 Bronchitis N — 250,000
24–105 1.11 M 2/01 Bronchitis Y RSV-B 136
24–178 2.21 M 11/00 Bronchiolitis Y PIV3 Positive ( 225)
24–194 1.88 M 12/00 Bronchitis Y — 1,950,000
24–202 2.91 M 12/00 Bronchiolitis Y RSV-A 12,400
24–230 2.38 M 1/01 Bronchiolitis Y — 2,290,000
24–232 2.63 M 1/01 Bronchiolitis Y — 11,400,000
34–162 0.48 F 10/01 Bronchitis N — 91,200,000
43–10 2.12 M 11/00 Bronchiolitis Y — Positive ( 225)
43–15 0.45 M 12/00 Bronchiolitis N RSV-A Positive ( 225)
43–18 0.51 F 12/00 Croup N — 28,600
HCoV-NL63-positive samples with a high viral load and undetectable levels of other respiratory viruses are shown in bold.
aThe patient number is preceded by the code of the medical centre: 10 is Freiburg SJK; 11 is Freiburg UKL; 20 is Dresden; 30 is Bochum; 40 is Hamburg; 12 and 13 are Freiburg; 22, 23, and 24 are Dresden; 34 is Bochum; 43 is Hamburg.
bNosocomial infection.
DOI: 10.1371/journal.pmed.0020240.t002
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Hospitalised HCoV-NL63-positive patients are frequently co-
infected with RSV. Nevertheless, several severe disease cases
that required uptake in the intensive care unit were linked
exclusively to HCoV-NL63 infection in this and our previous
survey [1].
Croup is a common manifestation of LRTI in children. The
cause is generally assumed to be a respiratory virus and PIV1
has frequently been implicated [12]. Among the 69 samples of
patients analysed with croup, croup was indeed frequently
linked to PIV1 (14.5%), but PIV3 (15.9%), RSV-A (13.0%),
PIV2 (7.2%), and RSV-B (1.4%) were also detected in a
considerable percentage of samples. HCoV-NL63 could be
detected in 17.4% of these croup patients and was therefore
the most frequently identiﬁed respiratory virus for croup.
Since most of the samples tested were derived from the year
2000–2001, we cannot exclude that the high percentage of
HCoV-NL63-positive samples is due to a strong viral activity
in this particular year, and long-term studies are needed to
determine whether HCoV-NL63 infections occur in cycles
peaking every two to three years as observed for other
respiratory viruses.
Croup has been reported to occur mostly in boys, and it
shows a peak occurrence in the second year of life and
predominantly in the late fall or early winter season [12].
HCoV-NL63 infection seems to follow these trends: the ratio
of boys infected to girls infected is 10:4, the median age in the
outpatient group with HCoV-NL63 is 1.55 y, and this virus is
circulating mainly in the winter months. Thus, it will be of
interest to study the underlying biological reasons for the
increased susceptibility of young boys to HCoV-NL63, as this
may also explain the higher number of male patients with
croup. A preferential occurrence in boys has been described
for other respiratory diseases including asthma [13], and
human coronavirus infections have previously been associ-
ated with exacerbations of asthma [14]. It will therefore also
be of interest to study this link for HCoV-NL63.
Results from the PRI.DE study indicated that co-infections
with multiple respiratory viruses are rare (1.5% of all samples
tested; [8]). In contrast, we report detection of more than one
viral RNA in 59% of HCoV-NL63-positive samples, which
represents 3% of the 949 samples tested. Most co-infections
are with RSV-A, probably because of the high percentage of
RSV-A infections and an overlap in seasonality. In the winter
season the percentage of RSV-positive samples per month
can exceed 50% and even the overall difference in
percentage of RSV-positive samples among HCoV-NL63-
negative and -positive samples was not signiﬁcant (Fisher’s
exact test, two-tailed). This contrasts with results obtained for
PIV1- and PIV3-positive patients, for whom co-infection with
RSV is rarely observed (data not shown). Therefore, infection
with RSV seems to reduce infection by PIV1 and PIV3 (or vice
versa), but not infection by HCoV-NL63 (or vice versa).
Quantitative PCR analysis for HCoV-NL63 revealed a
signiﬁcantly lower HCoV-NL63 viral load in patients co-
infected with RSV or PIV3 than in patients infected with
HCoV-NL63 alone. This interference effect might be ex-
plained by direct competition for the same target cell in the
respiratory organs or an elevated activation status of innate
immune responses. Prolonged persistence of HCoV-NL63 at
low levels is another explanation. The HCoV-NL63 load was
found to vary with respect to the time of sampling relative to
the time of disease onset, with the higher viral loads in early
samples (day 1 or 2 after disease onset). This most likely
reﬂects viral clearance by the immune system. This timing
effect may also relate to the differences in HCoV-NL63 load
in single versus double infections. For instance, an initial
HCoV-NL63 infection may set the stage for a subsequent RSV
infection. At the time that this second virus is causing
symptoms and NPS samples are collected, the HCoV-NL63
infection may already be under control by the immune
system.
The initial study on HCoV-NL63 in patients from
Amsterdam with respiratory tract illness listed 20% co-
infections, which is signiﬁcantly lower that the 59% that we
report in the present study. Differences in handling of the
clinical samples may in part explain this. NPS samples were
taken in a standardised manner and immediately frozen in
liquid nitrogen in the PRI.DE study. Nucleic acid extraction
was performed immediately after defrosting. Such optimal
sampling and subsequent handling may allow the detection of
lower HCoV-NL63 loads (as observed mainly in co-infec-
tions). In contrast, the Amsterdam samples were frozen and
defrosted repeatedly before nucleic acid isolation, which may
Figure 2. HCoV-NL63 Viral Load in Single and Double Infections
The median viral load in the two groups is indicated (in red) together
with the p-value, showing a significant difference between the singly
HCoV-NL63-infected group and the group with a co-infection of either
RSV or PIV3.
DOI: 10.1371/journal.pmed.0020240.g002
Table 3. Respiratory Viruses Associated with Croup
Virus Croup
(n ¼ 69)
Non-Croup
(n ¼ 867)
Odds Ratio
(95%
Confidence
Interval)
a
Odds Ratio
(95%
Confidence
Interval)
b
HCoV-NL63 12 (17.4%) 37 (4.2%) 4.8 (2.4–9.7) 6.6 (3.1–14.2)
RSV-A/B 10 (14.5%) 327 (37.7%) 0.3 (0.1–0.6) 0.3 (0.2–0.7)
PIV1/2/3 26 (37.7%) 93 (10.7%) 5.0 (3.0–8.6) 4.2 (2.4–7.5)
INF A/B 0 (0%) 22 (2.5%) — —
aOdds ratios derived from bivariate analyses.
bOdds ratios derived from a common logistic regression model.
DOI: 10.1371/journal.pmed.0020240.t003
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Association of HCoV-NL63 Infection with Crouphave rendered the low load samples negative. This may also
explain the higher proportion of HCoV-NL63 positives
measured in the current study (5.2% versus 1.4%). Alter-
natively, HCoV-NL63 might cycle with periods of increased
activity like other respiratory viruses and peak every 2–3 y,
and the 5.2% incidence in 2000–2001 may represent such a
peak year.
In conclusion, our study revealed that HCoV-NL63 belongs
to the group of most frequently detected viruses in children
under 3 y of age with LRTI and that this virus is strongly
associated with croup. Recent articles on HCoV-NL63 show
that this virus is spread worldwide [15–19]. The virus has been
found in different parts of the world: Australia, Canada,
Japan, Belgium, and the United States. Thus, HCoV-NL63 is a
human respiratory virus that should be added to the list of
pathogens that can cause numerous LRTIs in young children.
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Patient Summary
Background Lower respiratory infections (those that are not just coughs
and colds) are very frequent in young children and can be serious. Most
infections are caused by viruses, the best known of which are respiratory
syncytial virus (RSV) and influenza virus (INF).
Why Was This Study Done? Recently, a new virus known as HCoV-NL63
has been discovered, which is a human coronavirus (SARS is another
coronavirus). Previous work has shown that this virus was present in a
child with bronchiolitis. The researchers wanted to know whether the
virus was associated with other respiratory diseases.
What Did the Researchers Do and Find? They looked at 949 samples
taken from children with lower respiratory infections in Germany
between 1999 and 2001. They found that the virus HCoV-NL63 was
more common in outpatients than inpatients, and that more than 40% of
children infected with only this virus had croup compared with around
6% of children who did not carry the virus.
What Do These Findings Mean? Although the numbers of all the
children infected with this new virus was not high, these results do
suggest that this virus is a cause of croup in some children and may be
the third most common cause of lower respiratory infections in this
group. More work needs to be done to see whether this is true in other
years and other countries.
Where Can I Get More Information Online? MedlinePlus has Web
pages on croup:
http://www.nlm.nih.gov/medlineplus/ency/article/000959.htm
The Mayo Clinic has information about croup for parents:
http://www.mayoclinic.com/invoke.cfm?id¼DS00312
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